多替阿巴拉米片 使用说明

It is currently the only three-in-one compound drug containing dolutegravir (DTG), which integrates treatment drugs for different stages of viral infection in the same tablet. Patients only need to take one drug to achieve the effect of combined medication. The drug has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection. Today we will take a look at the instructions for use of Dote Abalamid Tablets.

1. Adults and adolescents (weighing at least 40 kg). For adults and adolescents, the recommended dosage of this product is one tablet, once a day. Adults or adolescents whose body weight is less than 40 kg should not be given as this product is a fixed-dose tablet and the dose cannot be reduced. 

  2. Doptabalamid tablets are fixed-dose tablets and cannot be used for patients who require dose adjustment. If discontinuation or dose adjustment of one of the active ingredients is necessary, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these drugs. 

3. If the patient misses taking a dose of Dota Abalami Tablets, and there are more than 4 hours left before the next dose, the patient should take this product as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

   4. In patients aged ≥65 years, there are limited data on the use of dolutegravir, abacavir and lamivudine. There is no evidence that older patients require different dosages than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when using dolutea paramid in this age group.

The English name of Dolutegravir tablets is Triumeq, which consists of three drugs: dolutegravir 50mg (dolutegravir) + abacavir 0.6g (abacavir) + lamivudine 0.3g (lamivudine). It is used for the treatment of HIV-1 infection. It is the only three-in-one compound drug containing dolutegravir. One tablet is taken once a day. It has the characteristics of high efficiency, good tolerance, high resistance barrier and few drug interactions.

The above is the content of the instructions for use, I hope it can help you!